A pioneering project that could one day help cure cancers and rare genetic diseases by sequencing the DNA of up to 100,000 NHS patients is one step closer to fruition
A pioneering project that could one day help cure cancers and rare genetic diseases by sequencing the DNA of up to 100,000 NHS patients is one step closer to fruition

Thousands of NHS patients to have DNA sequenced to help cancer research

US company, Illumina, chosen by government to lead £100m genome project in Cambridge

Emily Dugan
Sunday 20 July 2014 19:53
Comments

A pioneering project that could one day help cure cancers and rare genetic diseases by sequencing the DNA of up to 100,000 NHS patients is one step closer.

The Government has chosen an American gene-sequencing company, Illumina, to carry out the sequencing at its site in Cambridgeshire, it has emerged. Regulatory papers filed in the US confirm a contract is in the final stages of negotiation for the £100m project.

Although other countries are also pursuing mass DNA sequencing projects, the ambitious 100K Genome Project has been described as unique in scale and scope.

Research jobs are already being advertised for the programme, in which volunteers will discover intimate details about their genome, such as the presence of any high-risk cancer genes. All records will then be published online as a free tool for scientists.

Researchers say the risk to privacy is outweighed by the benefits of the huge-scale research, which could unlock the genetic secrets to cancer and other diseases.

Regulatory papers confirming a deal between the UK Government and Illumina were filed in Washington earlier this month. There are already advertisements on Totaljobs.com for posts in Cambridgeshire. One sought a research associate for a “high visibility” project sequencing thousands of genomes.

While the number of genomes to be sequenced is 100,000, the total number of people participating in the study is likely to be closer to 70,000. This is because for cancer patients Genomics England, which is organising the project, intends to obtain the sequence of both their inherited DNA as well as that of their cancers.

Talks began with potential bidders, including the Chinese Beijing Genomics Institute, earier this year.

Then, the average cost of completing a genome was between $3,000 and $4000 (£1,755 and £2,341). In January Illumina announced it had found the technology to sequence a genome for $1,000, or £585. Called the Hiseq X Ten, it consists of 10 machines, each costing more than half a million pounds. Users of the technology reportedly say it still costs closer to £1,000 to make a genome.

Illumina bought up the Cambridge genome company BlueGnome in 2012. It was founded in 2002 by Cambridge scientists renowned for work on the genome.

A Department of Health spokesman said: “We want the NHS to be the best healthcare system in world. That means being at the cutting edge of DNA technology to drive up cancer survival and cure rare diseases.

“In 2012, the Prime Minister announced a £100m investment to sequence 100,000 genomes by 2017. Excellent progress is being made and we will be setting out further details in the coming weeks.”

Announcing the launch of the project in 2012, David Cameron said: “By unlocking the power of DNA data, the NHS will lead the global race for better tests, better drugs and above all better care.

We are turning an important scientific breakthrough into a potentially life-saving reality for NHS patients across the country.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in